Download Ketamine for Treatment-Resistant Depression Ebook PDF

Ketamine for Treatment-Resistant Depression

Ketamine for Treatment-Resistant Depression
The First Decade of Progress

by Sanjay J. Mathew,Carlos A. Zarate, Jr.

  • Publisher : Springer
  • Release : 2016-11-25
  • Pages : 155
  • ISBN : 3319429256
  • Language : En, Es, Fr & De
GET BOOK

This book brings together an international group of clinicians and researchers from a broad swath of inter-related disciplines to offer the most up-to-date information about clinical and preclinical research into ketamine and second-generation “ketamine-like” fast-acting antidepressants. Currently available antidepressant medications act through monoaminergic systems, are ineffective for many individuals suffering from depression, and are associated with a delayed onset of peak efficacy of several months. The unexpected emergence of ketamine, an anesthetic N-methyl-D-aspartate (NMDA) receptor antagonist, as a rapid-acting antidepressant has reinvigorated CNS drug discovery research and catalyzed investigation in patient populations historically ignored in antidepressant drug development programs, particularly treatment-resistant patients and those with suicidality. Recent industry and academic research efforts have coalesced to explore NMDA receptor and glutamatergic molecular targets that lack ketamine’s psychotomimetic side effects and abuse liability but retain its rapid onset of efficacy. However, many fundamental questions remain regarding the neurobiological mechanisms underlying ketamine’s rapid antidepressant effects and the puzzling persistence of benefits observed in some patients following a single dose. This book examines how insights from these studies are forging new conceptual models of the neurobiology of stress-related affective, anxiety, and addictive disorders and the nature of treatment resistance. It also discusses how ketamine’s rapid antidepressant effects provide a scientific platform to facilitate innovation in clinical trial designs pertaining to patient selection, choice of control group, outcome measures, and dose-optimization. This book brings together data and insights from this rapidly expanding and extraordinarily promising field of study. Readers will be able to extract integrated themes and useful insights from the material contained in these diverse chapters and appreciate the paradigm-shifting contributions of ketamine to modern psychiatry and clinical neuroscience research.

Ketamine for Treatment-Resistant Depression

Ketamine for Treatment-Resistant Depression
Neurobiology and Applications

by Gustavo H. Vazquez,Carlos A. Zarate,Elisa Brietzke

  • Publisher : Academic Press
  • Release : 2020-10-01
  • Pages : 168
  • ISBN : 0128210346
  • Language : En, Es, Fr & De
GET BOOK

Ketamine for Treatment-Resistant Depression: Neurobiology and Applications provides a simple, evidence-based overview for neuropsychiatrists and translational researchers on this medication, its mechanisms of actions, eligibility of patients for treatment, and the preparation and implementation of ketamine clinics. Provides efficacy research on ketamine as a treatment for depression Identifies best practices for clinical use, both long-term and acute Discusses the molecular mechanisms and neurobiology of action

Ketamine for Depression

Ketamine for Depression
A Book

by Dr. Stephen J. Hyde

  • Publisher : Xlibris Corporation
  • Release : 2015-09-04
  • Pages : 222
  • ISBN : 1503509532
  • Language : En, Es, Fr & De
GET BOOK

Given the unacceptably high rates of suffering, disability and premature death experienced by people with treatment-resistant depression and the surprisingly low rates of problems arising from the use of ketamine to treat the disorder, this is a therapy that all patients and their doctors should be discussing. This book summarises the research that has been carried out into ketamine for the treatment of depression over the past 15 years and, most importantly, describes different ways of using ketamine that are both practical and cost–effective. Currently most ketamine therapy is given intravenously in specialised clinics at considerable expense, but the author has successfully treated patients with low-dose sublingual ketamine and his patients have been able to safely take this at home. Profits from the sales of this book will assist further research into the use of ketamine for the treatment of depression.

Repeated Intranasal Ketamine for Treatment-resistant Depression – the Way to Go? Results from a Pilot Randomised Controlled Trial

Repeated Intranasal Ketamine for Treatment-resistant Depression – the Way to Go? Results from a Pilot Randomised Controlled Trial
A Book

by Anonim

  • Publisher : Unknown Publisher
  • Release : 2021
  • Pages : 329
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK

Background: Ketamine research in depression has mostly used intravenous, weight-based approaches, which are difficult to translate clinically. Intranasal (IN) ketamine is a promising alternative but no controlled data has been published on the feasibility, safety and potential efficacy of repeated IN ketamine treatments. Methods: This randomised, double-blind, placebo-controlled pilot study compared a 4-week course of eight treatments of 100 mg ketamine or 4.5 mg midazolam. Each treatment was given as 10 separate IN sprays, self-administered 5 min apart. The study was stopped early due to poor tolerability after five treatment-resistant depressed participants were included. Feasibility, safety (acute and cumulative), cognitive and efficacy outcomes were assessed. Plasma ketamine and norketamine concentrations were assayed after the first treatment. Results: Significant acute cardiovascular, psychotomimetic and neurological side effects occurred at doses 100 mg ketamine. No participants were able to self-administer all 10 ketamine sprays due to incoordination; treatment time occasionally had to be extended (45 min) due to acute side effects. No hepatic, cognitive or urinary changes were observed after the treatment course in either group. There was an approximately two-fold variation in ketamine and norketamine plasma concentrations between ketamine participants. At course end, one participant had remitted in each of the ketamine and midazolam groups. Conclusions: IN ketamine, with the drug formulation and delivery device used, was not a useful treatment approach in this study. Absorption was variable between individuals and acute tolerability was poor, requiring prolonged treatment administration time in some individuals. The drug formulation, the delivery device, the insufflation technique and individual patient factors play an important role in tolerability and efficacy when using IN ketamine for TRD.

11 - THE USE OF SUBCUTANEOUS KETAMINE FOR TREATMENT-RESISTANT DEPRESSION

11 - THE USE OF SUBCUTANEOUS KETAMINE FOR TREATMENT-RESISTANT DEPRESSION
A Book

by Mariane Quieroti Rodrigues

  • Publisher : Unknown Publisher
  • Release : 2017
  • Pages : 329
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK

Introduction: Major depressive disorder is highly common with up to 50% to 60% of the patients not achieving adequate response following antidepressant treatment. In this scenario, ketamine emerges as an important alternative to conventional treatments, with its action of being an antagonist of N-methyl- D-aspartate (NMDA) receptor, once its has a quick and effective action. Ketamine is most frequently administered intravenous. However, oral, sublingual, transmucosal, intranasal, subcutaneous (SC), and intramuscular routes of administration have also been examined.Aim: This study aims to investigate whether SC ketamine is effective in the treatment of unipolar major depression and if it has more effective and sustainable response than electroconvulsivetherapy (ECT).Methods: Participants will be comprised of patients with unipolar depression resistant to conventional treatment, men and women, aged u2265 18 across a range of ethnicities, recruited from General Hospital Servidor of State of Su00e3o Paulo, Brazil. Participants will be separeted in two groups. The first one will recieve a SC administration of ketamine in the dose of 0,5mg/kg weekly, for 6 weeks. The second will be submitted to ECT treatment, two sessions a week, for at least 8 sessions. The response of each treatment will be evaluated and compared by MADRS questionnaire.Results: We expect that SC ketamine has a good response in the treatment of major depression and that it has a similar response compared to ECT.Conclusion: SC ketamine, once it is a secure, quick and simple procedure, is a promising alternative to the available treatments.

Intravenous Ketamine for Adults with Treatment-Resistant Depression Or Post-Traumatic Stress Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines

Intravenous Ketamine for Adults with Treatment-Resistant Depression Or Post-Traumatic Stress Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines
A Book

by Anonim

  • Publisher : Unknown Publisher
  • Release : 2019
  • Pages : 329
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK

KETAMINE FOR TREATMENT‐RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE.

KETAMINE FOR TREATMENT‐RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE.
A Book

by Anonim

  • Publisher : Unknown Publisher
  • Release : 2016
  • Pages : 329
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK

Abstract : There is an urgent need for more rapidly effective pharmacotherapies for major depressive disorder and bipolar disorder (BP) that are efficacious and tolerable for depressed patients who respond poorly to conventional treatments. Multiple controlled trials have now demonstrated a rapid, nonsustained antidepressive response to a single intravenous infusion of ketamine. Early controlled studies of intranasal or serial infusion therapy appear promising. The effective dose for depression is lower than the typical anesthetic doses, and side‐effects are generally mild and transient. The data investigating the adjunctive use of concurrent ketamine in the course of electroconvulsive therapy (ECT) for depression do not suggest efficacy or tolerability. The therapeutic potential of ketamine has stimulated considerable excitement among clinicians, patients, and industry, and has led to the increasing use of ketamine as an off‐label substitute for ECT and other antidepressive treatments. This clinical review of ketamine will assess the evidence‐based use of ketamine and initial clinical implications of further development of a potentially novel treatment for rapid reduction of symptoms in depressed patients.

Ketamine

Ketamine
From Abused Drug to Rapid-Acting Antidepressant

by Kenji Hashimoto,Soichiro Ide,Kazutaka Ikeda

  • Publisher : Springer Nature
  • Release : 2020-03-05
  • Pages : 189
  • ISBN : 9811529027
  • Language : En, Es, Fr & De
GET BOOK

This book presents the latest data from basic research and clinical trials supporting the effectiveness of ketamine as a treatment for depression, bipolar disorder, and suicidal behavior, setting these positive findings within the context of the serious problem of ketamine abuse. The first part of the book focuses on the evidence regarding ketamine abuse, with specific reference to Asian countries, and discusses countermeasures and complication management. It then addresses the mechanisms underlying the antidepressant and side effects of ketamine, which have remained elusive, describing and discussing important new research findings. Further, it explains insights gained from whole brain imaging in rodents and from behavioral pharmacology, and presents evidence regarding the role of gut microbiota, the NMDA receptor GluN2D subunit, and the lateral habenula in the actions of ketamine. These advances form the basis for the safer use of ketamine in patients with treatment-resistant depression and are expected to lead to the development of new antidepressants.

Intravenous Ketamine for Treatment of Major Depressive Disorder in a Patient with a History of Repetitive Traumatic Brain Injuries

Intravenous Ketamine for Treatment of Major Depressive Disorder in a Patient with a History of Repetitive Traumatic Brain Injuries
A Book

by John William III

  • Publisher : Unknown Publisher
  • Release : 2017
  • Pages : 329
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK

INTRODUCTION: Depression is the most common psychiatric disorder that occurs following a Traumatic Brain Injury. To date, there are limited studies demonstrating the effectiveness of current treatments for this disorder and even less for those with repetitive injuries or rTBIs. Ketamine has been demonstrated to be effective in successfully treating depression and helping with damaged connectivity within the brain. It can be hypothesized that Ketamine may help with both of these areas that many TBI patients face after injury. This particular case report describes the successful treatment of a patient with a history of rTBIs who struggled with depression for the past several years. CASE PRESENTATION: Mr. M is as 51 year old single caucasian male who presented to the Actify Neurotherapies Treatment Center for treatment of his Major Depressive Disorder. He had been depressed for five years but refused oral medication treatment due to fears over side effects. He presented with anergia, amotivation, feelings of sadness, anhedonia, impaired concentration and guilt/worthlessness with a QIDS score of 20 (Severe Depression) and GAD-7 of 18 (Severe Anxiety). Previous neuropsychological records revealed some cognitive impairment likely attributed to his multiple head injuries which included being hit over the head in an alley leading to amnesia for one month along with permanent anosmia. After completing a course of five Ketamine treatments, his symptoms either completely resolved or vastly improved as measured by the Levine Treatment Resistant Depression Scale (LRDTS). CONCLUSION: This case appears to be the first published report of a patient with multiple TBIs/rTBIs and Major depressive disorder successfully treated with intravenous ketamine. Overall, this illustrates the potential role that Ketamine may play in the treatment of psychiatric sequelae in individuals with a history of rTBIs. Ketamine has been demonstrated to increase BDNF and increase synaptogenesis which should encourage further research for brain injured individuals. Ketamine is also believed to potentially have neuroprotective effects as well which need to be further studied. Those with a history of one TBI are also at increased risk of having further rTBIs and therefore further increasing the chances of a depressive disorder. If one might be able to treat the individual before the repetitive event occurs, it may lead to quicker resolution of symptoms and may even decrease the chances of a subsequent event from occurring. Further studies are necessary to validate and replicate the symptom resolution of the above case but indicates that this treatment may be a potential viable rapid treatment option for those struggling without relief in sight.

Physiology of Behavior

Physiology of Behavior
A Book

by Neil R. Carlson

  • Publisher : Pearson College Division
  • Release : 2010
  • Pages : 730
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK

This revised edition incorporates the latest discoveries in the rapidly changing fields of neuroscience and physiological psychology and offers the most comprehensive and integrative coverage of research and theory in contemporary behavioural neuroscience.

New Scientist

New Scientist
A Book

by Anonim

  • Publisher : Unknown Publisher
  • Release : 2007
  • Pages : 329
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK

Development and Validation of an Animal Model of Treatment Resistant Depression

Development and Validation of an Animal Model of Treatment Resistant Depression
A Book

by Sarel Jacobus Brand

  • Publisher : Unknown Publisher
  • Release : 2017
  • Pages : 373
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK

Biomarkers -- Depression -- FSL -- Gene-environment -- Imipramine -- Ketamine -- Noradrenalin -- PTSD -- Serotonin -- Treatment resistance -- Venlafaxine -- Behandelingsweerstandigheid -- Biomerkers -- Depressie -- Geen-omgewing -- Imipramien -- Ketamien -- PTSV -- Venlafaksien.

I Fell in Love with My Ketamine Nurse

I Fell in Love with My Ketamine Nurse
A Book

by Siobhan Bledsoe

  • Publisher : Createspace Independent Publishing Platform
  • Release : 2017-11-20
  • Pages : 42
  • ISBN : 9781979736176
  • Language : En, Es, Fr & De
GET BOOK

This book tells the journey of a woman's trial with the experimental, and nascent, Ketamine Infusion treatment which combats medicine resistant depression. She completed the intensive treatment in the summer of 2017, catalyzed by heartbreak but also chemical depression, and continues to do maintenance appointments monthly. Although heavy subject matter, the author strives to make severe depression less stigmatized and taboo, and does this through a flirty and cheeky prism of writing this "about" her nurse, who affectionately (metaphorically and literally) held her hand through this process. The graphics, done by Saba Moeel, move from black and white to color as the trip progresses. In the end, she finds alleviation from her depression by way of the solace Ketamine provided her.

07 - KYNURENINE PATHWAY AS A TARGET AND BIOMARKER OF THE ANTIDEPRESSANT EFFECT OF KETAMINE

07 - KYNURENINE PATHWAY AS A TARGET AND BIOMARKER OF THE ANTIDEPRESSANT EFFECT OF KETAMINE
A Book

by Fabien Vinckier

  • Publisher : Unknown Publisher
  • Release : 2017
  • Pages : 329
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK

IntroductionIn recent decades, comprehensive evidence has accumulated that inflammation might be implied in the etiology of major depressive disorder besides monoamine imbalance classically described. In inflammatory conditions, the degradation of tryptophan is prioritized towards the production of kynurenine, leading to the production by microglial cells of quinolinic acid (QUIN), an excitotoxic NMDA receptor agonist. Ketamine is then a very promising antidepressant, and its NMDA antagonism might counteract QUIN accumulation. ObjectivesIn this study, the immune-modulating capacities of ketamine was investigated in depressed patients by examining the effect of ketamine treatment on tryptophan metabolites plasma levels. Methods15 treatment-resistant depressed in-patients received a cure of ketamine infusions (0.5 mg/kg intravenously), one or two times per week. Before and after each infusion, depression severity was assessed with the MADRS and plasma levels of tryptophan, kynurenine, kynurenic acid (KYNA), and QUIN were measured by HPLC and mass spectrometry. ResultsWe observed that pre-treatment KYNA/QUIN is a predictor of MADRS score after a ketamine infusion and after a whole cure of ketamine independently to depression severity (beta=0.28u00b10.07, p=0.0002 and beta=1.05u00b10.35, p=0.016 respectively). The variation of QUIN after a ketamine infusion is also a predictor of the percentage of variation in MADRS score after a ketamine infusion (beta=0.35u00b10.14, p=0.015). ConclusionsKetamine acts not only by counteracting QUIN on NMDA receptors but by reducing its production. As the tryptophan metabolism pathway is mainly supported by microglia in the brain, these findings underpin the immune-modulatory capacity of ketamine, suggesting microglia as a key therapeutic target and QUIN as a biomarker of ketamine response.

Improvised Medicine: Providing Care in Extreme Environments, 2nd edition

Improvised Medicine: Providing Care in Extreme Environments, 2nd edition
A Book

by Kenneth V. Iserson

  • Publisher : McGraw Hill Professional
  • Release : 2016-01-07
  • Pages : 688
  • ISBN : 0071847634
  • Language : En, Es, Fr & De
GET BOOK

Deliver quality healthcare in the most challenging field conditions Comprehensive yet compact, practical, and enduring, Improvised Medicine: Providing Care in Extreme Environments, Second Edition, is the one book to toss into your bag when going to practice medicine in global, disaster, or other resource-poor settings, including theaters of war, regions of civil unrest, and economically deprived areas. Full of practical clinical pearls and field-tested strategies, this indispensable guide provides detailed instructions on how to work successfully outside of your comfort zone. It demonstrates how to devise effective treatment solutions when the traditional tools (medications, equipment, and staff) are unavailable or when providing care outside your primary area of expertise. In any crisis, from power failures and computer crashes to floods, tsunamis, and earthquakes, knowing how to deal with the unique challenges encountered saves lives and communities. This reference gives you that knowledge and inspires innovative crisis resolution. FROM REVIEWS OF THE FIRST EDITION: "Dr Iserson has given us a most remarkable book. Many readers may be familiar with David Werner's lay healthworker book, Where There Is No Doctor; this new volume could be titled Where There Is a Doctor–But No Stuff. Drawing from his experience providing care in international, wilderness, and disaster settings, he has compiled an impressive collection of bare-bones equipment and work-around strategies to provide the best possible care in resource-poor settings. While presenting many creative examples, the purpose of the book is not to offer an exhaustive list of solutions to missing resource challenges but to inspire creativity in readers who may find themselves needing to improvise." -- Family Medicine “There is a lot of material here and, if nothing else, it may motivate more people to practice low-tech medicine and be willing to go where health care is dependent more on caring than on cost. I recommend this book to anyone who must practice in austere environments, and it will be in my rucksack when I respond to the next disaster.” – The Journal of Emergency Medicine FEATURES: ·Simple-to-follow directions, diagrams, and illustrations describing practical techniques and improvised equipment necessary to provide quality care during crises ·Contains improvisations in anesthesia and airway management, dentistry, gynecology/obstetrics, infectious disease/laboratory diagnosis, internal medicine, otolaryngology, pediatrics and malnutrition, orthopedics, psychiatry, and surgery·Covers situational analysis and basic needs in a crisis; specific triage, diagnosis, and stabilization efforts; medical interventions for surgical and non-surgical problems; and debunks some commonly reported improvised techniques ·Features public health measures, basic disaster communication techniques, post-disaster forensics, a model hospital disaster plan, and innovative patient-transport methods·New to the second edition: More concisely written, more extensively illustrated, and updated improvisations and references LEARN HOW TO:·Make an endotracheal tube in seconds ·Perform digital-oral and blind-nasotracheal intubations ·Make plaster bandages for splints/casts ·Give open-drop ether, ketamine drips, and halothane ·Use subcutaneous/intraperitoneal rehydration/transfusion ·Make ORS and standard nutrition formulas ·Clean, disinfect, and sterilize equipment for reuse ·Warm blood units in seconds inexpensively ·Take/view stereoscopic x-rays with standard equipment ·Quickly and easily stop postpartum hemorrhage ·Fashion surgical equipment from common items ·Build an evaporative refrigerator·Make esophageal and precordial stethoscopes ·Quickly improvise a saline lock ·Make ECG electrode/defibrillator pads and ultrasound gel·Evacuate patients easily from high-rise hospitals

Basic and Clinical Pharmacology 15e

Basic and Clinical Pharmacology 15e
A Book

by Bertram G. Katzung,Anthony J. Trevor

  • Publisher : McGraw Hill Professional
  • Release : 2020-11-22
  • Pages : 1328
  • ISBN : 1260452328
  • Language : En, Es, Fr & De
GET BOOK

Master key pharmacological concepts and practices with the most comprehensive, authoritative guide available Presented in full-color and packed with hundreds of illustrations, Basic and Clinical Pharmacology is the wide-ranging, engaging guide students have counted on for decades. Organized to reflect the course sequence in many pharmacology courses and in integrated curricula, the guide covers the important concepts students need to know about the science of pharmacology and its application to clinical practice. This edition has been extensively updated to provide expanded coverage of transporters, pharmacogenomics, and new drugs Delivers the knowledge and insight needed to excel in every facet of pharmacology!. Encompasses all aspects of medical pharmacology, including botanicals and over-the-counter drugs Major revisions of the chapters on immunopharmacology, antiseizure, antipsychotic, antidepressant, antidiabetic, anti-inflammatory, and antiviral drugs, prostaglandins, and central nervous system neurotransmitters New chapter on the increasingly relevant topic of cannabis pharmacology Each chapter opens with a case study, covers drug groups and prototypes, and closes with summary tables and diagrams that encapsulate important information Revised full-color illustrations provide more information about drug mechanisms and effects and help clarify important concepts Trade Name/Generic Name tables are provided at end of each chapter for easy reference when writing a chart order or prescription Includes descriptions of important new drugs released through May 2019 New and updated coverage of general concepts relating to recently discovered receptors, receptor mechanisms, and drug transporters

Current Medical Research and Opinion

Current Medical Research and Opinion
A Book

by Anonim

  • Publisher : Unknown Publisher
  • Release : 2003
  • Pages : 329
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK

Molecular Neuropharmacology: A Foundation for Clinical Neuroscience, Fourth Edition

Molecular Neuropharmacology: A Foundation for Clinical Neuroscience, Fourth Edition
A Book

by Eric J. Nestler,Steven E. Hyman,Robert C. Malenka

  • Publisher : McGraw Hill Professional
  • Release : 2020-09-05
  • Pages : 592
  • ISBN : 1260456919
  • Language : En, Es, Fr & De
GET BOOK

Publisher's Note: Products purchased from Third Party sellers are not guaranteed by the publisher for quality, authenticity, or access to any online entitlements included with the product. The definitive guide to treating neurologic and psychiatric disorders with drugs and other approaches Fully updated with the latest research and drugs, Nestler, Hyman, & Malenka’s Molecular Neuropharmacology, Fourth Edition, is the leading guide to molecular neuroscience. Providing an in-depth look at the neuropharmacological fundamentals of the nervous system, it delivers the knowledge and insight you need to master the pathophysiology of neurologic and psychiatric disorders. Complete with tables, diagrams, and figures clearly illustrating the intricacies of neurochemistry and molecular neuroscience, this peerless guide reviews the effects of drug action (organized by drug category) to enhance your understanding of major disease mechanisms, and it explains the pathophysiology and neuropharmacology of all major neurologic and psychiatric disorders. Concise overviews of the effects of drugs and other treatment approaches are presented in a way that boosts your understanding and retention of critical concepts. Nestler, Hyman, & Malenka’s Molecular Neuropharmacology provides a deep dive into: General principles of neurophar¬macology Nervous system function Drugs that act on neuronal and glial function Major neurotrans¬mitter systems in the brain and spinal cord Atypical neurotransmitters, including peptides, growth factors, and cytokines Major brain and spinal cord systems at the molecular, cellular, and circuit levels in health and disease

Mind, Brain, and Drug

Mind, Brain, and Drug
An Introduction to Psychopharmacology

by Dawson Hedges,Colin Burchfield

  • Publisher : Pearson College Division
  • Release : 2006
  • Pages : 366
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK

"Comprehensive yet manageable, Mind, Brain, and Drug: An Introduction to Psychopharmacology serves as an excellent guide for students to this increasingly important field."--Jacket.

The Praeger International Collection on Addictions: Characteristics and treatment perspectives

The Praeger International Collection on Addictions: Characteristics and treatment perspectives
A Book

by Angela Browne Miller

  • Publisher : Praeger
  • Release : 2009
  • Pages : 1609
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK